Nutlin-3a

Catalog No.S8059

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Nutlin-3a Chemical Structure

Nutlin-3a Chemical Structure
Molecular Weight: 581.49

Validation & Quality Control

Quality Control & MSDS

Product Information

  • Compare Mdm2 Inhibitors
    Compare Mdm2 Products
  • Research Area

Product Description

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Targets p53/MDM2 interaction [3]
(Cell-free assay)
IC50 90 nM
In vitro Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MV-4-11M{PJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2K5c2lEPTB;MD62NVI{PyEQvF2=MWfTRW5ITVJ?
H4NW[5b3NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXYelBKSzVyPUCuOlYzQCEQvF2=MoLaV2FPT0WU
PA-1M{TFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TzNmlEPTB;MD64O|A6PiEQvF2=MX7TRW5ITVJ?
NKM-1NVHsVYU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjuc3hKSzVyPUGuNFQ6OzFizszNNYjONYpKW0GQR1XS
NEC8NVG5dpdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;CN3FuUUN3ME2xMlIyPTd{IN88US=>MULTRW5ITVJ?
EoL-1-cellM33RRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTFwMk[3NFEh|ryPMYrTRW5ITVJ?
K5MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHxTWM2OD1zLkSyNFczKM7:TR?=M{CwZnNCVkeHUh?=
QIMR-WILNWHaXXlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnnc5JKSzVyPUGuOlA5PTRizszNM4TsPHNCVkeHUh?=
MOLT-16MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzKTWM2OD1zLke4OlA1KM7:TR?=NYrKRnlOW0GQR1XS
CHP-212MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDYTWM2OD1zLkixN|Y6KM7:TR?=M1TUWXNCVkeHUh?=
CTB-1NWrie4ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTJwMEKyOFYh|ryPMkXkV2FPT0WU
MOLT-4MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\WTWM2OD1{LkOyPFU{KM7:TR?=M{HPOXNCVkeHUh?=
A101DMkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfENFdHUUN3ME2yMlM2ODFizszNNWK5ZWpMW0GQR1XS
DOHH-2NF7nXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTJwNEKyO|kh|ryPM3PYWnNCVkeHUh?=
ES4Mlm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXVdHFrUUN3ME2yMlQ{OTV3IN88US=>NIXVXlBUSU6JRWK=
SW780MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoS0TWM2OD1{LkWwPFg{KM7:TR?=M3TufnNCVkeHUh?=
VA-ES-BJNHv3R29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTWOWVKSzVyPUKuOVQyOSEQvF2=MUjTRW5ITVJ?
RPMI-8866MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTJwNU[yNVQh|ryPNH\wfYNUSU6JRWK=
ML-2NVzIWHVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33zfWlEPTB;Mj61OlU4PiEQvF2=NYLXN25FW0GQR1XS
MSTO-211HNXno[3E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTJwNUe0OVEh|ryPM4jnXXNCVkeHUh?=
JVM-3M3nr[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3oWIhYUUN3ME2yMlU6OzJ2IN88US=>M{jpd3NCVkeHUh?=
A3-KAWM13F[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4m2[GlEPTB;Mj62NVgyQCEQvF2=M3\DOXNCVkeHUh?=
DK-MGNIqxcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7sTWM2OD1{Lk[yOFcyKM7:TR?=NEnyXppUSU6JRWK=
LNCaP-Clone-FGCNV7hbZNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTJwNkSzNVgh|ryPNVHVZWZCW0GQR1XS
HT-144M1TrPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYqwW2hXUUN3ME2yMlY1PTd5IN88US=>MYPTRW5ITVJ?
NB69M4nObGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoeyTWM2OD1{Lk[1N|M1KM7:TR?=M1jIbHNCVkeHUh?=
A172Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULJdW9uUUN3ME2yMlY4PTh6IN88US=>NEjN[pFUSU6JRWK=
RS4-11MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HYbGlEPTB;Mj63NlQxPyEQvF2=M{HYV3NCVkeHUh?=
DU-4475NU\3So5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrWdmZKSzVyPUKuO|k2ODJizszNMoPzV2FPT0WU
SJSA-1M161cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nUT2lEPTB;Mj64NlU2PiEQvF2=M1\U[XNCVkeHUh?=
BV-173NVruWHVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnX2TWM2OD1{Lki0OFM6KM7:TR?=MWDTRW5ITVJ?
U-2-OSNHfzV|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTJwOUGwO{DPxE1?NEfvRW9USU6JRWK=
CHP-134NU\POXV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLtTWM2OD1{LkmzPFgzKM7:TR?=NVvnSXY1W0GQR1XS
D-502MGMlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTJwOUexOVQh|ryPMkmxV2FPT0WU
KS-1NXK4W2FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoP2TWM2OD1|LkCxOlI{KM7:TR?=MYnTRW5ITVJ?
A204NYjtNlFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTNwMEW1PFgh|ryPM4HVNnNCVkeHUh?=
KGNM1zkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;HeGlEPTB;Mz6wPFQ6PiEQvF2=M1;TTXNCVkeHUh?=
NCI-H292NGXXNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fFPWlEPTB;Mz6xNlAzQCEQvF2=MVnTRW5ITVJ?
CAKI-1M2\6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;sTWM2OD1|LkGyOlk1KM7:TR?=MYLTRW5ITVJ?
C2BBe1Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVuxVFlGUUN3ME2zMlE4ODJ4IN88US=>MoK1V2FPT0WU
NB10MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnPTWM2OD1|LkKwPVY3KM7:TR?=NIjYSXpUSU6JRWK=
MHH-NB-11MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3ITWM2OD1|LkK2PFI4KM7:TR?=NVzKXXNvW0GQR1XS
NCI-SNU-1NYjsc|B{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTNwMke4OFMh|ryPMXPTRW5ITVJ?
HCT-116NEOwZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPQTWM2OD1|LkOwN|M2KM7:TR?=MnXMV2FPT0WU
G-401NYjqOFRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4GxfmlEPTB;Mz6zOlMzOiEQvF2=NIS3ZVNUSU6JRWK=
MN-60MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDoTWM2OD1|LkS0NFkzKM7:TR?=NWT1T5FRW0GQR1XS
SW982NF7H[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2j2eGlEPTB;Mz61NFg1QCEQvF2=MYPTRW5ITVJ?
RKONV;XbVdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTNwNUO5N|Yh|ryPMoqzV2FPT0WU
D-283MEDMoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTNwNUe5PFYh|ryPMUTTRW5ITVJ?
LB996-RCCMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fJV2lEPTB;Mz62NlU2QCEQvF2=NEDDS5NUSU6JRWK=
A549M3rrdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTNwNkO1OVIh|ryPMmjWV2FPT0WU
LB2241-RCCNGL6Z5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLVbFJOUUN3ME2zMlY2PzB6IN88US=>NFrVTlhUSU6JRWK=
SK-HEP-1M4i1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHCZnFRUUN3ME2zMlc1Ojl5IN88US=>MYfTRW5ITVJ?
G-402NXrOSFN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\iTWM2OD1|LkiwPFMzKM7:TR?=NH7YS2JUSU6JRWK=
GOTOM2jtXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrkc4xKSzVyPUOuPFQ{OzNizszNMljGV2FPT0WU
LOXIMVINETlUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVz1do1DUUN3ME2zMlg2Pjd3IN88US=>M{TOV3NCVkeHUh?=
NH-12NVvSW3NsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fqTmlEPTB;ND6wNVk2QSEQvF2=M1TjPHNCVkeHUh?=
CTV-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1G5NWlEPTB;ND6wO|k4OyEQvF2=NGK5W2tUSU6JRWK=
CP50-MEL-BNIq0OWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\3TWlEPTB;ND6yOFM6OiEQvF2=MXvTRW5ITVJ?
RH-18NULKfIpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfmO4I{UUN3ME20MlI4PzB4IN88US=>NVLNUY1sW0GQR1XS
NB17MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3rjT2lEPTB;ND6zNVc3QCEQvF2=M3nNV3NCVkeHUh?=
A375NVS1b2MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLUPIhKSzVyPUSuN|M2OjRizszNNGjSfWZUSU6JRWK=
IST-MES1NYi1W2VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTRwNEG0NVEh|ryPM4HOPHNCVkeHUh?=
MZ2-MELMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVn3epd{UUN3ME20MlUxOTV3IN88US=>M2jFSHNCVkeHUh?=
CAL-54NFWxVYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TPfGlEPTB;ND61N|AyQSEQvF2=MWnTRW5ITVJ?
NCI-H28MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXiwNVJ3UUN3ME20MlYzPzF5IN88US=>MoPHV2FPT0WU
D-247MGNHyxXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTRwN{WwO|Ih|ryPM1\CXXNCVkeHUh?=
NCI-H460NXLiTZF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HtSWlEPTB;ND65NVEzPyEQvF2=MWXTRW5ITVJ?
MCF7NH3UT|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLTW2pKSzVyPUWuOFQzPDRizszNM1XTcnNCVkeHUh?=
697NX3KfFF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rYVmlEPTB;NT60OFU2KM7:TR?=M3[xcnNCVkeHUh?=
ONS-76MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzw[lNKSzVyPUWuOVcxODlizszNM1;pd3NCVkeHUh?=
C32MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTVwNkCwNlkh|ryPNIHIT|lUSU6JRWK=
OS-RC-2M2K4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\mTWM2OD13LkezPFg4KM7:TR?=Mn\IV2FPT0WU
MEL-HOMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\CeGlEPTB;NT64OVY3PyEQvF2=NXLxZ5NbW0GQR1XS
LoVoNEeyOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrJTWM2OD14LkCxOlI1KM7:TR?=NFPvTHlUSU6JRWK=
AGSMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETjbZlKSzVyPU[uNVQ5OjhizszNM1\mdnNCVkeHUh?=
GI-ME-NNVflbWtrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fjcmlEPTB;Nj6yNlQzOSEQvF2=M1;M[XNCVkeHUh?=
H-EMC-SSMkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\Ib3RKSzVyPU[uN|g3KM7:TR?=NEjYNplUSU6JRWK=
RVH-421NG\p[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{K2PGlEPTB;Nj60NlQzQCEQvF2=NYjPO2luW0GQR1XS
SW954M4[4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEe2NnhKSzVyPU[uOVU2PzJizszNNIjsWpZUSU6JRWK=
NB5NWWzVJdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nxVGlEPTB;Nj61OlE5OyEQvF2=NUTnV3VCW0GQR1XS
NCI-H2122NH7F[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TDfmlEPTB;Nj61PFc6OyEQvF2=MYLTRW5ITVJ?
AM-38NVG5[oIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPsUYNPUUN3ME22Mlc2PjN7IN88US=>NWPpfIdLW0GQR1XS
KNS-81-FDNIrGNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTZwN{[0PVQh|ryPMnzHV2FPT0WU
LS-513Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4q2N2lEPTB;Nj63PVAzPiEQvF2=MmfpV2FPT0WU
A427MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDNUoppUUN3ME22Mlg4QDJ7IN88US=>Mmj5V2FPT0WU
WM-115M1fiVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDRTHNKSzVyPU[uPVMzOyEQvF2=MYTTRW5ITVJ?
COLO-829NUPIb4VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfzUGxKSzVyPUeuNlQyQDhizszNM{j3fnNCVkeHUh?=
NCI-H1650M3vBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTdwM{myNlgh|ryPMonRV2FPT0WU
NCI-H358MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1KzXmlEPTB;Nz60OFg4QSEQvF2=MUDTRW5ITVJ?
HT-1080NHuz[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnRN2JFUUN3ME23MlQ5OjV2IN88US=>NEPj[pdUSU6JRWK=
HCC2218M3fnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1X1O2lEPTB;Nz62Nlk4KM7:TR?=NVnOOYJYW0GQR1XS
NCI-H661NELrUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2H1[WlEPTB;Nz64O|A3QSEQvF2=M{Hsb3NCVkeHUh?=
KM-H2M4HifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIj6TY9KSzVyPUeuPFg3QTRizszNNV\Rdo12W0GQR1XS
RPMI-2650NEj6XFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnaTZdZUUN3ME23Mlk1PDF2IN88US=>NVTyenBTW0GQR1XS
NCI-H226M1Lydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTuU5FKSzVyPUiuNlEyOjJizszNM{nGenNCVkeHUh?=
MKN45MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRThwMk[2NFIh|ryPMWPTRW5ITVJ?
D-392MGMn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHjZmtKSzVyPUiuOVI4OjJizszNMYDTRW5ITVJ?
RCC10RGBNV3nO|VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTHR3dlUUN3ME24Mlg3Pjl3IN88US=>M3;3[HNCVkeHUh?=
CAL-51MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfkUINYUUN3ME25MlExOjVzIN88US=>MVzTRW5ITVJ?
COLO-678NGPaV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmi4TWM2OD17LkOyPFEyKM7:TR?=MnvSV2FPT0WU
SK-MEL-24MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTlwNUW4OVYh|ryPMnG0V2FPT0WU
SK-MEL-30M1fzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVyxfGxCUUN3ME25Mlk1PDd4IN88US=>MUDTRW5ITVJ?
MMAC-SFMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDoelBmUUN3ME2xNE4{QTZzIN88US=>NXznXmc2W0GQR1XS
NTERA-S-cl-D1NHnjTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jY[mlEPTB;MUCuOlUxQCEQvF2=MoHLV2FPT0WU
NB12M1TlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7JTWM2OD1zMT61NFMh|ryPMmXLV2FPT0WU
UACC-257NEHZNmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXTTWM2OD1zMT64Olk2KM7:TR?=NVf0PWFJW0GQR1XS
LAN-6NH;KdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzRbYpGUUN3ME2xNU46QTJ6IN88US=>MY\TRW5ITVJ?
SW1573MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV35PXVvUUN3ME2xNk4{ODh4IN88US=>MlGxV2FPT0WU
NMC-G1MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfLXHBKSzVyPUGyMlQyPzVizszNMUnTRW5ITVJ?
SHP-77NHz4VHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTF{LkW1O|Qh|ryPNYTXbWI2W0GQR1XS
IGROV-1NUH0NIlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlTBTWM2OD1zMj62OVc{KM7:TR?=MWPTRW5ITVJ?
22RV1M4OxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnZRo5zUUN3ME2xNk45ODV7IN88US=>MWjTRW5ITVJ?
SK-MEL-3NWPkcVhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1Pie2lEPTB;MUOuN|k4OyEQvF2=MYDTRW5ITVJ?
NCI-H1563MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7mNJU1UUN3ME2xN{41OjB{IN88US=>MYLTRW5ITVJ?
IGR-1NU\kV21WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTF2LkCzOFch|ryPM{n4cnNCVkeHUh?=
EW-3NGq0VIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEf1XYFKSzVyPUG0MlE3OzlizszNM1XYS3NCVkeHUh?=
JEG-3M2WxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXETWM2OD1zND60PVU{KM7:TR?=M1G2VnNCVkeHUh?=
ES3NGmyemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vzTGlEPTB;MUSuOlU3OiEQvF2=MVPTRW5ITVJ?
MDA-MB-175-VIIMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljzTWM2OD1zND63NVEyKM7:TR?=Ml3aV2FPT0WU
P30-OHKMoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnr0TWM2OD1zNT6wOFk3KM7:TR?=NWn2d|dZW0GQR1XS
GP5dNHrVW|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVj0d5RoUUN3ME2xOU4yPDZ4IN88US=>MnPkV2FPT0WU
HMV-IINGPueohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUG2T45yUUN3ME2xOU4{OzN|IN88US=>MVvTRW5ITVJ?
COLO-679M4G2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrEZ2YyUUN3ME2xOU42ODFizszNMXzTRW5ITVJ?
JARMmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mon4TWM2OD1zNT63NlA2KM7:TR?=NVrJSIl[W0GQR1XS
NCI-H1666NUCxc|VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvUd45KSzVyPUG1Mlk{QTlizszNM2jYRXNCVkeHUh?=
SW48M2jVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M16yUmlEPTB;MUWuPVUyPiEQvF2=MYrTRW5ITVJ?
NCI-H720NH\HSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVrIWWlNUUN3ME2xOU46QTh7IN88US=>MVfTRW5ITVJ?
HT-1197M{nDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEW0eHFKSzVyPUG2MlA{PTJizszNNX\lOG92W0GQR1XS
HL-60MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3mbJdKSzVyPUG2MlA{QDRizszNMXHTRW5ITVJ?
BENMlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXhUnZKSzVyPUG2MlU3OzhizszNNGjMeIVUSU6JRWK=
HAL-01NUHZXZRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HSUmlEPTB;MU[uPFkxQSEQvF2=NVjoe21pW0GQR1XS
SW900MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTF4LkmxN|Ih|ryPNGfi[YdUSU6JRWK=
SBC-1NWHLfFJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfndppNUUN3ME2xO{42PDJ7IN88US=>MlHpV2FPT0WU
SH-4NF;US21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTF5LkW4OFEh|ryPMVPTRW5ITVJ?
UACC-62NF7NcW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDsPHZ{UUN3ME2xO{44PjN5IN88US=>M{DNdXNCVkeHUh?=
BHT-101NVPvTm5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnqfpBKSzVyPUG5Mlg4ODVizszNMYPTRW5ITVJ?
DBNU\6XFA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrvTWM2OD1{MT61OlQ6KM7:TR?=M3KzfnNCVkeHUh?=
SK-MEL-1MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rpWWlEPTB;MkGuOVg4OiEQvF2=NWj4R3I3W0GQR1XS
NCI-H747MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TRXWlEPTB;MkKuO|M4QSEQvF2=NFf1VnVUSU6JRWK=
SK-LU-1NF7FV5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Moq3TWM2OD1{Mz6zOVI1KM7:TR?=MXnTRW5ITVJ?
KG-1NHPRcWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7p[Yh[UUN3ME2yN{41QTR4IN88US=>M3rLdHNCVkeHUh?=
LXF-289M4XaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\mT|dFUUN3ME2yN{44OTRizszNM3LZSHNCVkeHUh?=
HCC1954MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTtTWM2OD1{ND64PFQ1KM7:TR?=MXLTRW5ITVJ?
Ramos-2G6-4C10NGLEXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTJ4LkS5PFEh|ryPM{ns[HNCVkeHUh?=
DBTRG-05MGMm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnhTWM2OD1{Nj62OFg5KM7:TR?=M1jh[HNCVkeHUh?=
NCI-H2052M4TpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRTJ5LkW2PFQh|ryPMWXTRW5ITVJ?
RMG-IMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2Tqb2lEPTB;MkmuOFE{QSEQvF2=NUjDSVJbW0GQR1XS
H9MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEK3WZhKSzVyPUOxMlMxODhizszNNEnMXYVUSU6JRWK=
GR-STNYj5bYRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTN{LkS0OVMh|ryPNVXSb5ZDW0GQR1XS
Mo-TMmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmHOTWM2OD1|Mj61NFQ3KM7:TR?=MVPTRW5ITVJ?
SW1088MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTN{Lkm4NFEh|ryPNUjJVWQ3W0GQR1XS
LB2518-MELMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTN|LkC3PVch|ryPMV7TRW5ITVJ?
NCI-H82NEjhTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHzTWM2OD1|Mz6xOlYyKM7:TR?=NEG5W3NUSU6JRWK=
LAMA-84NWfZZ5ByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXKTWM2OD1|ND62NFc{KM7:TR?=NFXje|BUSU6JRWK=
KYSE-450Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmW1TWM2OD1|ND62O|c3KM7:TR?=MWrTRW5ITVJ?
LU-99ANUTjSFNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfWTWM2OD1|NT6wNFA4KM7:TR?=M4L1O3NCVkeHUh?=
BE-13M{jZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTmTWM2OD1|NT62OVQ2KM7:TR?=NGeyNWRUSU6JRWK=
GAKMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLGTWM2OD1|NT62PVUh|ryPMoHHV2FPT0WU
NCI-H1573NWfrfnhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTN3Lki4NVgh|ryPM2q0UHNCVkeHUh?=
AsPC-1M2fQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIracllKSzVyPUO2MlE2OjdizszNMV7TRW5ITVJ?
HDLM-2NILLNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37NS2lEPTB;M{[uN|E3KM7:TR?=NW\Xco5ZW0GQR1XS
NCI-H441MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XqS2lEPTB;M{euNFY6OSEQvF2=M1vrZ3NCVkeHUh?=
CAL-27MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTN5LkeyN|Eh|ryPNEfPOJVUSU6JRWK=
OVCAR-3MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zQS2lEPTB;M{muN|E5OSEQvF2=M{LteXNCVkeHUh?=
RPMI-8226NIjN[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XGR2lEPTB;M{muOVk5KM7:TR?=M1i0fHNCVkeHUh?=
EFO-21NX2xe3QxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\NN|dKSzVyPUSwMlU5OTRizszNM17KO3NCVkeHUh?=
SNU-C2BMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrmbXlKSzVyPUSxMlUxQDRizszNMkGyV2FPT0WU
VM-CUB-1MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3O4UmlEPTB;NEOuPFA{PyEQvF2=NV3NTmtGW0GQR1XS
NCI-H2087M4Xk[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPSdoZKSzVyPUS1MlAzOzNizszNNF\md3VUSU6JRWK=
EW-16MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTR4LkOxN|ch|ryPM2fIU3NCVkeHUh?=
SK-N-ASMnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTR4LkexOlch|ryPNFLXW3hUSU6JRWK=
COR-L105MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\rSGlEPTB;NE[uPFg2PyEQvF2=MV\TRW5ITVJ?
DELMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;KfmhKUUN3ME20PE4xPDJ7IN88US=>M2K0enNCVkeHUh?=
JVM-2M3jVVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDjVoNKSzVyPUS4MlA2PThizszNNFLqdo5USU6JRWK=
KARPAS-45M1r0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\TO4JKSzVyPUS5MlQ2OzhizszNMUDTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.

Protocol(Only for Reference)

Kinase Assay: [3]

Biacore studies Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel

Cell Assay: [2]

Cell lines OSA, T778, RMS13, U2OS, SaOS-2
Concentrations ~5 μM
Incubation Time 120 h
Method SRB

Animal Study: [1]

Animal Models SJSA-1 xenograft
Formulation 1% Klucel, 0.1% Tween 80
Dosages 50, 100, 200 mg/kg twice daily
Administration oral

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tovar C, et al. Proc Natl Acad Sci U S A, 2006, 103(6), 1888-1893.

[2] Ohnstad HO, et al. BMC Cancer, 2011, 11(211), 1-11.

view more

Chemical Information

Molecular Weight (MW) 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms (-)-Nutlin-3
Solubility (25°C) * In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water <1 mg/mL (<1 mM)
In vivo 2% DMSO+1% hydroxyethyl cellulose+0.2% Tween 80 15 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-Piperazinone, 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Mdm2 Products

  • Idasanutlin (RG-7388)

    Idasanutlin (RG-7388) is a potent and selective p53-MDM2 inhibitor with IC50 of 6 nM.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • Nutlin-3

    Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

  • NSC 207895

    NSC 207895 suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.

  • Nutlin-3b

    Nutlin-3b is a p53/MDM2 antagonist or inhibitor with IC50 value of 13.6 μM, 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nutlin-3a.

  • YH239-EE

    YH239-EE, the ethyl ester of YH239, is a potent p53-MDM2 antagonist and an apoptosis inducer.

  • Z-VAD-FMK

    Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

    Features:A key compound for apoptosis studies.

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

Recently Viewed Items

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us